<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12259">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947347</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1141-CA</org_study_id>
    <nct_id>NCT02947347</nct_id>
  </id_info>
  <brief_title>Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the addition of ibrutinib will result in
      prolongation of progression-free survival (PFS) when compared with rituximab alone in
      treatment naïve subjects with follicular lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2-5 years</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Treatment Naive Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>(Part 1) ibrutinib + rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 560mg of ibrutinib and rituximab 375mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Part 1) placebo + rituximab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo and rituximab 375mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Part 2) ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 560mg of ibrutinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Part 2) placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibrutinib</intervention_name>
    <description>ibrutinib 560mg administered orally</description>
    <arm_group_label>(Part 1) ibrutinib + rituximab</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to match ibrutinib</intervention_name>
    <description>placebo capsules to match ibrutinib administered orally</description>
    <arm_group_label>(Part 1) placebo + rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>rituximab 375mg/m^2 IV</description>
    <arm_group_label>(Part 1) ibrutinib + rituximab</arm_group_label>
    <arm_group_label>(Part 1) placebo + rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibrutinib</intervention_name>
    <description>ibrutinib 560mg administered orally</description>
    <arm_group_label>(Part 2) ibrutinib</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to match ibrutinib</intervention_name>
    <description>placebo capsules to match ibrutinib administered orally</description>
    <arm_group_label>(Part 2) placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a)
             Ann Arbor Stage II, III or IV disease.

          -  Measurable disease

          -  Subjects 70 years of age or older; OR subjects 60-69 years of age who have one or
             more comorbidities.

          -  Meets one or more Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.

          -  Adequate hematologic function within protocol-defined parameters.

          -  Adequate hepatic and renal function within protocol-defined parameters.

          -  ECOG performance status score of 0-2.

        Exclusion Criteria:

          -  Transformed lymphoma

          -  Prior treatment for follicular lymphoma

          -  Central nervous system lymphoma or leptomeningeal disease

          -  Currently active, clinically significant cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alina Smith</last_name>
    <phone>+1-855-427-8846</phone>
    <email>pharmacyclics@medcomsol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>October 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
